The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.
Recall -- Firm Press Release
FDA posts press releases and other notices of recalls and market withdrawals from the firms involved as a service to consumers, the media, and other interested parties. FDA does not endorse either the product or the company.
APP Pharmaceuticals Issues A Nationwide Voluntary Recall
Of Irinotecan Hydrochloride Injection
Debra Lynn Ross, ABC
Director, Corporate Communications
APP Pharmaceuticals, Inc.
FOR IMMEDIATE RELEASE - March 25, 2011 - APP Pharmaceuticals, Inc., (APP) announced today that it has issued a voluntary recall of five lots of Irinotecan Hydrochloride Injection, which is used for recurrent or progressive metastatic colorectal cancer. This recall is being conducted as a precautionary measure and there have been no reports to dates of adverse events related to the recalled products.
APP has voluntarily recalled lots 870DE00301, 870CZ00301, 870DE00101, 870DE00201 and 870DE00401of Irinotecan Hydrochloride Injection 100mg/5mL, (20mg/mL), 5mL Single Dose Vial and Irinotecan Hydrochloride Injection, 40mg/2mL, (20mg/mL), 2mL Single Dose Vial. APP decided to take this action due to an atypical trend in customer complaints associated with lot 870DE00301. Three customers reported that they discovered a particulate in the product solution in lot 870DE00301. Upon further investigation of the returned vials, the particulate was confirmed to be a fungal microbial contaminant.
APP’s root cause investigation is ongoing; however, APP’s preliminary investigation indicates that only products from lot 870DE00301 were involved. As a precautionary measure and in consultation with the U.S. Food and Drug Administration the lots produced immediately before and after lot 870DE00301 are also being recalled
APP has initiated this voluntary recall of Irinotecan Injection to the retail level due to the discovery of foreign material and non-sterility in one lot of Irinotecan injection. Non-sterility of a chemotherapeutic product administered via the intravenous route has the potential to result in infections, which could be fatal, especially in patients who are immunocompromised. APP is not aware of any adverse patient events resulting from this product and is continuing its diligent investigation of the situation. Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this product. This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.
APP has placed a copy of the Dear Healthcare Professional letter on its Web site, www.APPpharma.com. Customers with product in stock that has a matching lot number to the Recall Notice should follow the directions listed in the Recall Notice.
Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA’s MedWatch Adverse Event Reporting program online, or via regular mail or by fax.
· Online: www.fda.gov/medwatch/report.htm
· Regular Mail: use postage-paid, pre-addressed Form FDA 3500 available at:
www.fda.gov/MedWatch/getforms.htm. Mail to address on the pre-addressed form.
· Fax: 1-800-FDA-0178
About APP Pharmaceuticals, Inc.
APP Pharmaceuticals, Inc. is a fully-integrated pharmaceutical company that develops, manufactures and markets injectable pharmaceutical products with a primary focus on the oncology, anti-infective, anesthetic/analgesic and critical care markets. The company offers one of the most comprehensive product portfolios used in hospitals, long-term care facilities, alternate care sites and clinics within North America and manufactures a comprehensive range of dosage formulations. Fresenius Kabi Pharmaceuticals Holding, Inc., a wholly owned subsidiary of Fresenius Kabi AG, acquired APP Pharmaceuticals, Inc. on September 10, 2008. For more information about APP Pharmaceuticals, Inc., please visit the company’s Web site at www.APPpharma.com.
The statements contained in this news release that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this news release include statements regarding our expectations, beliefs, hopes, goals, intentions, initiatives or strategies, including statements regarding the demand, supply and distribution of our Irinotecan Hydrochloride Injection.. Because these forward-looking statements involve risks and uncertainties, there are important factors that could cause actual results to differ materially from those in the forward-looking statements. These factors include, but are not limited to, the availability and pricing of ingredients used in the manufacture of pharmaceutical products and the ability to successfully manufacture products in a time-sensitive and cost effective manner. Additional relevant information concerning risks can be found in the Fresenius Kabi Pharmaceuticals Holding, Inc. 10-K for the fiscal year ending December 31, 2010 and other documents the company has filed with the Securities and Exchange Commission.
The information contained in this news release is as of the date of this release. Fresenius Kabi Pharmaceuticals Holding, Inc. does not assume any obligation to update or revise these forward-looking statements to conform the statement to actual results, new information, developments or changes in the Company’s expectations.
Recalled Product Photos Are Also Available on FDA's Flickr Photostream.